AGA issues updated guidance on HDV management
-
by Amy Pfeiffer
November 6, 2025
-
3 min
The American Gastroenterological Association has issued a Clinical Practice Update on hepatitis delta virus (HDV) management, emphasizing its association with hepatitis B virus (HBV) and the increased risks of cirrhosis and liver cancer. Approximately 30,000 to 60,000 people in the U.S. have active HDV infection, especially prevalent among specific high-risk groups. The AGA recommends universal screening for HDV in chronic HBV patients, beginning with anti-HDV antibody tests. Current treatment options remain limited, but promising new therapies are under development to enhance efficacy and safety for HDV patients.
1. AGA guidelines focus on HDV management related to HBV infection. 2. Significant health risks include cirrhosis and liver-related mortality. 3. Universal screening for HDV in chronic HBV patients is recommended. 4. Pegylated interferon-alpha is currently the only approved treatment in the U.S. 5. New therapies are under trial, with potential for improved outcomes. 6. Screening rates among high-risk populations remain low. 7. Patients with HDV should undergo surveillance for liver cancer.
Listen Tab content
